|Chemical and physical data|
|Molar mass||356.4387 g/mol g·mol−1|
|3D model (JSmol)|
Apricoxib is an experimental anticancer drug. It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer. Development was abandoned in 2015 due to poor clinical trial results.
- Kirane, A. (2012). “Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer”. Clinical Cancer Research. 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.